statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Be Biopharma to use MaxCyte's Flow Electroporation technology and ExPERT platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc...

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MaxCyte price target lowered by $2 at BTIG, here's why

MaxCyte affirms FY24 guidance

MaxCyte reports Q4 EPS (5c), consensus (7c)

Investors considering a purchase of MaxCyte Inc (MXCT) shares, but cautious about paying the going market price of 4.26/share, might benefit from considering selling puts among the alternative...

Commit To Buy MaxCyte At $2.50, Earn 6.7% Annualized Using Options

Q4 2023 MaxCyte Inc Earnings Call Transcript

MaxCyte (NASDAQ:MXCT  Get Free Report)s stock had its outperform rating reiterated by investment analysts at William Blair in a report released on Wednesday, RTT News...

MaxCyte (NASDAQ:MXCT) Receives Outperform Rating from William Blair

Despite Challenges, Company Reiterates 2024 GuidanceRelated Stocks: MXCT...

MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD, March 12, 2024 MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

ROCKVILLE, Md., March 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Watchers	355
52-Wk Low	$2.45
52-Wk High	$5.55

Volume	483,295.00
52-Wk High	$5.55
52-Wk Low	$2.45

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.12	--	--	N/A
Q1'24	-$0.13	-$0.09	28.00%	BEAT
Q4'23	-$0.07	-$0.05	26.83%	BEAT
Q3'23	-$0.10	-$0.11	-8.98%	MISSED
Q2'23	-$0.10	-$0.10	-4.17%	MISSED

MXCT MaxCyte Inc

About

Feed

News

Sentiment

Earnings

Fundamentals